PORTFOLIO NEWS ORIC Pharmaceuticals Announces $85 Million Private Placement Financing June 26, 2023 Read More » Carmot Therapeutics Highlights Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 83rd American Diabetes Association Scientific Sessions June 23, 2023 Read More » Escient Pharmaceuticals Announces Positive Results From Phase 1 Study of EP262, A First-In-Class Oral MRGPRX2 Antagonist for Mast Cell Mediated Disorders June 20, 2023 Read More » Neurona Therapeutics Presents One-Year Data on the First Patient Treated with NRTX-1001 Cell Therapy in an Ongoing Phase I/II Trial for Drug-resistant Focal Epilepsy June 15, 2023 Read More » Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications June 14, 2023 Read More » Effector Therapeutics Raises a Total of $16.2M in Gross Proceeds From Two Recent Registered Direct Offerings June 9, 2023 Read More » Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke June 5, 2023 Read More » Eikon Therapeutics Acquires Global Rights to Clinical-Stage Assets and Announces Emerging Drug Development Pipeline June 01, 2023 Read More » eFFECTOR Therapeutics Announces Closing of $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules May 31, 2023 Read More » A2 Bio Announces First Patient Dosed in Phase 1 Clinical Trial of A2B530, a Novel Cell Therapy for the Treatment of Colorectal, Pancreatic and Non-small Cell Lung Cancers May 30, 2023 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
Carmot Therapeutics Highlights Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 83rd American Diabetes Association Scientific Sessions June 23, 2023 Read More »
Escient Pharmaceuticals Announces Positive Results From Phase 1 Study of EP262, A First-In-Class Oral MRGPRX2 Antagonist for Mast Cell Mediated Disorders June 20, 2023 Read More »
Neurona Therapeutics Presents One-Year Data on the First Patient Treated with NRTX-1001 Cell Therapy in an Ongoing Phase I/II Trial for Drug-resistant Focal Epilepsy June 15, 2023 Read More »
Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications June 14, 2023 Read More »
Effector Therapeutics Raises a Total of $16.2M in Gross Proceeds From Two Recent Registered Direct Offerings June 9, 2023 Read More »
Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke June 5, 2023 Read More »
Eikon Therapeutics Acquires Global Rights to Clinical-Stage Assets and Announces Emerging Drug Development Pipeline June 01, 2023 Read More »
eFFECTOR Therapeutics Announces Closing of $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules May 31, 2023 Read More »
A2 Bio Announces First Patient Dosed in Phase 1 Clinical Trial of A2B530, a Novel Cell Therapy for the Treatment of Colorectal, Pancreatic and Non-small Cell Lung Cancers May 30, 2023 Read More »
